# SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

> **NCT07141329** · PHASE2 · RECRUITING · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Focal Onset Seizures

## Interventions

- **DRUG:** SPN-817

## Key facts

- **NCT ID:** NCT07141329
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07141329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07141329, "SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07141329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*